(NASDAQ: DYN) Dyne Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 45.71%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 43.12%.
Dyne Therapeutics's earnings in 2025 is -$423,801,000.On average, 17 Wall Street analysts forecast DYN's earnings for 2025 to be -$516,111,289, with the lowest DYN earnings forecast at -$536,078,180, and the highest DYN earnings forecast at -$500,886,177. On average, 17 Wall Street analysts forecast DYN's earnings for 2026 to be -$485,461,111, with the lowest DYN earnings forecast at -$604,662,595, and the highest DYN earnings forecast at -$347,920,938.
In 2027, DYN is forecast to generate -$420,090,252 in earnings, with the lowest earnings forecast at -$670,447,646 and the highest earnings forecast at -$314,928,435.